Program
TQC3302
A development code. Also written as “TQC3302 inhalation spray”, “TQC3302 inhalation spray+Tiotropium bromide and olodaterol hydrochloride inhalation spray +Budesonide Powder for Inhalation” and “Tiotropium bromide and olodaterol hydrochloride inhalation spray +Budesonide Powder for Inhalation+ TQC3302 inhalation spray”.
In Sino Biopharmaceutical's pipeline, ICS/LAMA/LABA吸入喷雾剂 (布地奈德/噻托溴铵/奥达特罗吸入喷雾剂)
. Its studies are mostly in Pulmonary Disease, Chronic Obstructive, led by Sino Biopharmaceutical.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sino Biopharmaceutical | 10 open or running | phase 1since Nov 25, 2025 | Nov 25, 2025 | none ahead |
- Named in Sino Biopharmaceutical’s own pipeline as
TQC3302
, phase 1, as of Nov 16, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 25, 2025First study: phase 1 study in Pulmonary Disease, Chronic ObstructiveFirst studyNCT07267130 · 33 enrolled · China
TargetBeta
“ICS/LAMA/LABA吸入喷雾剂 (布地奈德/噻托溴铵/奥达特罗吸入喷雾剂)”the company's pipeline, read by Claude · source
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07267130Pulmonary Disease, Chronic Obstructive · China | 1 | Terminated | Aug 21, 2026 | 33 |
How it is read
Names in the registry
- “TQC3302 inhalation spray”, 2 entries
- “TQC3302 inhalation spray+Tiotropium bromide and olodaterol hydrochloride inhalation spray +Budesonide Powder for Inhalation”, 1 entry
- “Tiotropium bromide and olodaterol hydrochloride inhalation spray +Budesonide Powder for Inhalation+ TQC3302 inhalation spray”, 1 entry
- “Budesonide Powder for Inhalation+ TQC3302 inhalation spray+ Tiotropium bromide and olodaterol hydrochloride inhalation spray”, 1 entry
Codes read as this program: TQC3302.
Conditions, from the studies’ own filings
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.